Ulcerative Colitis and Crohn's Therapeutics Flashcards
What is the treatment for Mild UC
Dose
Duration
Mesalamine (5-ASA)
Induction: 3g daily by mouth
+ 1g once-twice/day rectally (ideally combo, especially if lower GI)
Maintenance: 2-3g daily by mouth
+/- 1g daily rectally
Duration
- 1-2 weeks for improvement, 4-6 weeks for remission
MOA of sulfasalazine
sulfapyridine + Mesalamine:
to prevent absorption of mesalamine (5-ASA) UNTIL it reaches site of action (colon)
Mesalamine is preferred
When is combo of oral and rectal mesalamine used in mild UC?
- Active left sided UC
- extensive UC
- Proctitis (lower part of GI)
What are Adverse effects of aminosalicylates (5)
Generally well-tolerated
Headache
Loss of appetite
Nausea/vomiting
Rash
Hair loss
When are corticosteroids used in mild treatment of UC?
What are the options?
Used when symptoms of UC has not improved after 4 weeks of 5-ASA
- Hydrocortisone once-twice/daily rectally via suppositories, foams, enemas
- Budesonide 9mg by mouth daily
Which biologics have conditional recommendation and not strong recommendation in UC (3)
Adalimumab
Mirikizumab
Fligotinib
What is the treatment for moderate-severe UC?
Do not use 5-ASAs
Go straight to anti-TNF agents + immunomodulator therapies
Which Ant-tnfs are used in UC (3)
- Infliximab (REMICADE) IV @ 0, 2, 6 weeks, then SC q2weeks
- Golimumab (SIMPONI) SC @ 0, 2 weeks, then SC q4weeks
- Adalimumab SC @ 0, 2 weeks, then SC q2weeks
- lower efficacy
Which immunomodulators can be added to anti-tnf (2)
- Azathioprine 50-100mg daily
- Mercaptopurine 25-50mg daily
What are adverse effects of anti-TNFa (8)
- Infusion reactions (for infliximab),
- headache
- rash
- infection
- reactivation of TB/Hep B
- cancer
- cardiac failure
- demyelination
What are the adverse effects of azathioprene and mercaptopurine (3) interactions (2)
ADRs
- bone marrow suppression
- infection
- GI toxicity
Interactions
- live vaccine limitations
- interacts with allopurinol
Which monoclonal antibody is used in UC and CD? Monitor for remission for how long?
Vedolizumab (ENTYVIO) IV @ 0, 2, 6 weeks, then SC q2weeks
Monitor for remission in 8-14 weeks
What are the more common AE reports in vedolizumab (entyvio) in clinical trials (2)
Nasopharyngitis
Headache
What are the IL-12/23 inhibitors used in UC and CD (3)
- Ustekinumab (STELARA) IV x1, then SC q8weeks
- both IL12/23 - Risankizumab (SKYRIZI) IV @ 0, 4, 8 weeks, then SC q8weeks
- IL-23 only
- higher efficacy - Mirikizumab IV @ 0, 4, 8 weeks, then SC q4weeks
- IL-23 only
- not as effective
- only for UC- not studied in CD
What are AEs for ustekinumab (3)
- Nasopharyngitis
- Headache
- opportunistic infections
What are the AEs for risankizumab and mirikizumab (2)
Similar to ustekinumab
- higher incidence of pain and redness at injection site
- lower risk of infection since it only targets IL-23
Which JAK inhibitors can be used in UC and CD
Upadacitinib 45mg daily x8 weeks, then 15mg daily
- JAK-1 only
Tofacitinib 10mg BID x8 weeks, then 5mg BID
- JAK-1,3 and to a lesser extent 2
- not used in CD
What are the adverse effects of the JAK inhibitors (5)
- High lipids
- CV events
- cancer
- clots
- infection